Novel Molecules in Diabetes Mellitus, Dyslipidemia and Cardiovascular Disease 2.0
Conflicts of Interest
List of Contributions
- Bakhashab, S.; Barber, R.; O’Neill, J.; Arden, C.; Weaver, J.U. Overexpression of miR-199b-5p in Colony Forming Unit-Hill’s Colonies Positively Mediates the Inflammatory Response in Subclinical Cardiovascular Disease Model: Metformin Therapy Attenuates Its Expression. Int. J. Mol. Sci. 2024, 25, 8087.
- Dłuski, D.F.; Cieśla, M.; Darmochwał-Kolarz, D. Circular RNA hsa_circ_0002268 (PHACTR1) Is Specific to Gestational Diabetes Mellitus in a Polish Pregnant Population. Int. J. Mol. Sci. 2024, 25, 7040.
- Höpfinger, A.; Schmid, A.; Karrasch, T.; Pankuweit, S.; Schäffler, A.; Grote, K. Cathelicidin Antimicrobial Peptide Levels in Atherosclerosis and Myocardial Infarction in Mice and Human. Int. J. Mol. Sci. 2024, 25, 2909.
- Dalle, S. Targeting Protein Kinases to Protect Beta-Cell Function and Survival in Diabetes Int. J. Mol. Sci. 2024, 25, 6425.
- Chatzianagnostou, K.; Gaggini, M.; Suman Florentin, A.; Simonini, L.; Vassalle, C. New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions. Int. J. Mol. Sci. 2024, 25, 6218.
- Sirca, T.B.; Mureșan, M.E.; Pallag, A.; Marian, E.; Jurca, T.; Vicaș, L.G.; Tunduc, I.P.; Manole, F.; Ștefan, L. The Role of Polyphenols in Modulating PON1 Activity Regarding Endothelial Dysfunction and Atherosclerosis. Int. J. Mol. Sci. 2024, 25, 2962.
- Haș, I.M.; Tit, D.M.; Bungau, S.G.; Pavel, F.M.; Teleky, B.-E.; Vodnar, D.C.; Vesa, C.M. Cardiometabolic Risk: Characteristics of the Intestinal Microbiome and the Role of Polyphenols. Int. J. Mol. Sci. 2024, 25, 13757.
References
- Piccirillo, F.; Mastroberardino, S.; Nusca, A.; Frau, L.; Guarino, L.; Napoli, N.; Ussia, G.P.; Grigioni, F. Novel Antidiabetic Agents and Their Effects on Lipid Profile: A Single Shot for Several Cardiovascular Targets. Int. J. Mol. Sci. 2023, 24, 10164. [Google Scholar] [CrossRef] [PubMed]
- Kuchay, M.S.; Farooqui, K.J.; Mishra, S.K.; Mithal, A. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. Adv. Exp. Med. Biol. 2021, 1307, 213–230. [Google Scholar] [PubMed]
- Rowlands, J.; Heng, J.; Newsholme, P.; Carlessi, R. Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Front. Endocrinol. 2018, 9, 672. [Google Scholar] [CrossRef] [PubMed]
- Kiec-Klimczak, M.E.; Pach, D.M.; Pogwizd, M.E.; Hubalewska-Dydejczyk, A.B. Incretins yesterday, pleiotropic gastrointestinal hormones today: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Recent Pat. Endocr. Metab. Immune Drug Discov. 2011, 5, 176–182. [Google Scholar] [CrossRef] [PubMed]
- Karagiannis, A.D.; Liu, M.; Toth, P.P.; Zhao, S.; Agrawal, D.K.; Libby, P.; Chatzizisis, Y.S. Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors from Molecular Biology to Clinical Translation. Curr. Atheroscler. Rep. 2018, 20, 20. [Google Scholar] [CrossRef] [PubMed]
- Scheen, A.J. Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke? Discordance between randomised controlled trials and observational studies. Diabetes Metab. 2023, 49, 101474. [Google Scholar] [CrossRef] [PubMed]
- Markowicz-Piasecka, M.; Sadkowska, A.; Huttunen, K.M.; Podsiedlik, M.; Mikiciuk-Olasik, E.; Sikora, J. An investigation into the pleiotropic activity of metformin. A glimpse of haemostasis. Eur. J. Pharmacol. 2020, 872, 172984. [Google Scholar] [CrossRef] [PubMed]
- Gheorghe, G.; Toth, P.P.; Bungau, S.; Behl, T.; Ilie, M.; Pantea Stoian, A.; Bratu, O.G.; Bacalbasa, N.; Rus, M.; Diaconu, C.C. Cardiovascular Risk and Statin Therapy Considerations in Women. Diagnostics 2020, 10, 483. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vesa, C.M.; Bungău, S.G. Novel Molecules in Diabetes Mellitus, Dyslipidemia and Cardiovascular Disease 2.0. Int. J. Mol. Sci. 2024, 25, 9527. https://doi.org/10.3390/ijms25179527
Vesa CM, Bungău SG. Novel Molecules in Diabetes Mellitus, Dyslipidemia and Cardiovascular Disease 2.0. International Journal of Molecular Sciences. 2024; 25(17):9527. https://doi.org/10.3390/ijms25179527
Chicago/Turabian StyleVesa, Cosmin Mihai, and Simona Gabriela Bungău. 2024. "Novel Molecules in Diabetes Mellitus, Dyslipidemia and Cardiovascular Disease 2.0" International Journal of Molecular Sciences 25, no. 17: 9527. https://doi.org/10.3390/ijms25179527